Skip to main content
Clinical Trials/NL-OMON49620
NL-OMON49620
Completed
Not Applicable

The PaPa Trial: Paracetamol as an adjunct to intrapartum Remifentanil/PCA. An RCT of multimodal pain management during labor. - The PaPa Trial

Reinier de Graaf Groep0 sites79 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Reinier de Graaf Groep
Enrollment
79
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
December 11, 2020
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Reinier de Graaf Groep

Eligibility Criteria

Inclusion Criteria

  • Pregnant, in labour, \>3 centimetres dilatation.
  • Pain request during labour, medication of choice: Remifentanil/ PCA.
  • Age 18 years and older.
  • Able to understand the written and verbal information about the PaPa Trial.

Exclusion Criteria

  • Refusal for participation in the PaPa Trial
  • No adequate communication possible (e.g. language barrier)
  • Use of other opioids, e.g. Pethidine of epidural analgesia \<4 hours prior to
  • start of Remifentanil as pain management.
  • Hypersensitivity for Paracetamol.
  • Liver\- of kidneydiseases
  • Alcohol abuse
  • Glucose\-6\-phosphate dehydrogenase
  • Use of other medication that contains Acetaminophen/ Paracetamol
  • Severe nutritional deficiency

Outcomes

Primary Outcomes

Not specified

Similar Trials